AtriCure (NASDAQ:ATRC) Updates Q4 2025 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its fourth quarter 2025 earnings guidance on Monday. The company provided EPS guidance of -0.210–0.180 for the period, compared to the consensus EPS estimate of -0.050. The company issued revenue guidance of $140.5 million-$140.5 million, compared to the consensus revenue estimate of $139.2 million. AtriCure also updated its FY 2025 guidance to EPS.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and an average price target of $52.44.

AtriCure Stock Down 3.3%

ATRC opened at $36.40 on Wednesday. The firm has a market cap of $1.81 billion, a P/E ratio of -59.67 and a beta of 1.40. The business’s fifty day simple moving average is $37.81 and its 200 day simple moving average is $35.84. AtriCure has a 52 week low of $28.29 and a 52 week high of $43.18. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last released its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. The company had revenue of $134.27 million for the quarter, compared to analyst estimates of $131.25 million. During the same period in the prior year, the firm earned ($0.17) EPS. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, equities research analysts anticipate that AtriCure will post -0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other AtriCure news, Director Sven Wehrwein sold 4,967 shares of AtriCure stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total transaction of $188,746.00. Following the transaction, the director directly owned 34,374 shares of the company’s stock, valued at $1,306,212. The trade was a 12.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Maggie Yuen sold 3,000 shares of AtriCure stock in a transaction on Friday, November 21st. The shares were sold at an average price of $35.72, for a total transaction of $107,160.00. Following the transaction, the director owned 11,371 shares in the company, valued at $406,172.12. The trade was a 20.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 18,166 shares of company stock worth $676,378 over the last three months. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On AtriCure

Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. acquired a new position in AtriCure during the 2nd quarter valued at approximately $37,000. Strs Ohio acquired a new stake in AtriCure in the first quarter worth $158,000. Tower Research Capital LLC TRC lifted its stake in AtriCure by 502.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,492 shares of the medical device company’s stock valued at $180,000 after buying an additional 4,581 shares during the last quarter. State of Tennessee Department of Treasury acquired a new position in shares of AtriCure during the second quarter valued at $184,000. Finally, Quadrant Capital Group LLC bought a new position in shares of AtriCure during the third quarter worth about $198,000. 99.11% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.